2 completed, 1 not yet recruiting, 1 unknown. 2 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Obesity in Diabetes: new trials by email Literature Review of Obesity in Diabetes trials Research Report on Obesity in Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide Treatment in Type 1 Diabetes Semaglutide 2.4mg, Semaglutide placebo - Obesity in Diabetes, Obesity/Therapy | Phase 3 | Not yet recruiting | Nordsjaellands Hospital | 122 | 2025-10-01 | 2025-08-08 |
| A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM MET097 Injection, Placebo - Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Completed | Pfizer | 133 | 2025-03-14 | 2026-06-12 |
| Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II) Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d) - Obesity, Insulin Resistance | Not applicable | Unknown | Augusta University | 30 | 2016-10-01 | 2019-11-20 |
| Obese Patients With Type 2 Diabetes Rimonabant (SR141716) - Obesity, Diabetes Mellitus, Non-Insulin-Dependent | Phase 3 | Completed | Sanofi | 1045 | 2001-10-01 | 2009-04-20 |
Obesity (4) · Diabetes Mellitus, Type 2 (2) · Insulin Resistance (2) · Weight Loss (2) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Hyperglycemia (1) · Hyperlipidemias (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Overweight (1)
Body Weight (4) · Glucose Metabolism Disorders (4) · Nutrition Disorders (4) · Overnutrition (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Endocrine System Diseases (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Overweight (3) · Body Weight Changes (2) · Diabetes Mellitus (2) · Hyperinsulinism (2) · Autoimmune Diseases (1) · Dyslipidemias (1)
Rimonabant (1) · Vitamin K 2 (1) · menaquinone 7 (1) · semaglutide (1)
Augusta University (1) · Nordsjaellands Hospital (1) · Pfizer (1) · Sanofi (1)
United States (3) · Argentina (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Norman K Pollock, PhD (1) · Thomas F Dejgaard, MD, ph.d., endocrinologist (1)